Successful Management of an Infected Implantable Cardioverter Defibrillator with Oral Antibiotics and without Removal of the Device (original) (raw)
Related papers
The treatment of patients with infected implantable cardioverter-defibrillator systems
The Journal of Thoracic and Cardiovascular Surgery, 1997
The purpose of this study was to evaluate the treatment of patients with infected implantable cardioverter-defibrillator systems. Methods: Retrospective analysis was done of the cases of 21 patients treated for implantable cardioverter-defibrillator infection during an ll-year period. Results: Of 723 cardioverter-defibrillator implantations (550 primary implants, 173 replacements), nine (1.2%) were complicated by early postoperative device-related infections. Late infections developed in two patients 19 and 22 months, respectively, after implantation. Ten other patients were transferred to our institution for treatment of cardioverter-defibrillator infection. The time from implantation to overt infection was 2.2 _+ 1.3 months, excluding the two late infections. The responsible organisms were Staphy~:occus aureus (9), Staphylococcus epidermidis (6), Streptococcus hemolyticus (1), gram-negative bacteria (3), Candida albicans (1), and Corynebacterium (1). ~Ml patients were treated with intravenous antibiotic drngs. Total system removal was done in 15 patients and partial removal in 2; in 4, the cardioverter-defibrillator system was not explanted. There were no perioperative deaths. A new implantable cardioverter-defibrillator system was reimplanted in 7 patients after 2 to 6 weeks of antibiotic therapy. Ten patients were treated without reimplantation (2 arrhythmia operation, 8 antiarrhythmic drngs). Four patients (3 patients without explantation and 1 with partial system removal) were treated with maintenance long-term antibiotic therapy. During a mean follow-up of 21-2.8 months, no patient had clinical recurrence of infection. One patient treated with antiarrhythmic drngs without system reimplantation died suddenly. Conclusions: Infections that involve implantable cardioverter-defibrillator systems can be safely managed by removing the entire system with reimplantation after intravenous antibiotic therapy. In selected patients in whom the risk for system explantation is high and anticipated life expectancy is short, long-term antibiotic therapy to suppress low-virulence infections may represent an acceptable alternative.
Clinical Microbiology and Infection, 2006
The prognosis for patients with ventricular arrhythmias has improved dramatically with the aid of implantable cardioverter-defibrillators (ICDs). Although infection is a serious complication that frequently causes dysfunction and loss of ICDs, the frequency, predisposing risk-factors, and clinical and microbiological features are only partially understood. This study describes a retrospective review of 423 procedures in 278 patients with ICD primary implants and replacements performed at a tertiary-care hospital. Generators were placed in either a pectoral (68%) or abdominal (32%) site, and electrodes were placed transvenously in 97% of the patients. Most (95%) interventions were performed in a one-stage procedure. Infection developed with ten (2.4%) implanted devices. Four cases occurred within 30 days of surgery ('early infections') and six occurred > 1 month after surgery ('late infections'). In univariate analysis, factors associated with the development of an early infection were: two-stage surgery, a sub-costal approach, and abdominal generator placement. In patients with late infections, a significant association was found with trauma or decubitus ulcer in the generator area. Infection presented with local signs without systemic complications. Seven of the ten patients required complete removal of the system.
Infections with Nonthoracotomy Implantable Cardioverter Defibrillators: Can These Be Prevented?
Pacing and Clinical Electrophysiology, 1998
Be Prevented? Nonthoracotomy ICDs are believed to be the best therapeutic modality for treatment of lifethreatening ventricular arrhythmias. Little is known about the risk of infection with initial implantation of these devices. We studied the incidence, clinical characteristics, and risk factors associated with infections in 1,831 patients with nonthoracotomy ICD from the Endotak-C nonthoracotomy lead registry of Cardiac Pacemakers, Inc. A transvenous lead was implanted in 950 patients (51.9%) and a combination transvenous plus subcutaneous patch was used in 881 patients (48.1%). Nine preselected data variables were studied, and all investigators identified as having patients with infections were personally contacted. Infections occurred in 22 (1.2%) of 1,831 patients receiving this nonthoracotomy ICD system. The mean time to infection was 5.7 ± 6.5 months (range 1-25 months). Staphylococci were isolated in 58% of patients with reported infection. The presence of a subcutaneous defibrillator patch system was associated with the development of infection. Six of 950 patients (0.63%) with a totally transvenous lead system developed infection versus 16 of 838 (1.9%) patients with a transvenous lead plus subcutaneous patch system configuration (P = 0.015,, with an unadjusted estimated odds ratio of 3.06 ). The risk of infection encountered with the nonthoracotomy ICD is low, estimated from our data to be 1.2%. Placement of a subcutaneous defibrillator patch appears to be an independent risk factor for development of infection. (PACE 1998; 21[Pt. I]:42-55) infection, implantable cardioverter defibrillator Implantable cardioverter defibrillators (ICDs) are well-established as a successful therapeutic modality for the treatment of patients with lifethreatening arrhythmias.^^" From the early development of the ICD, Mirowski and Mower appreciated the feasihility and desirability of nonthoracotomy systems.^~^^ However, due to the many formidable technical challenges encoun-Address for reprints: Peter N, Smith, M.D., FACC, Marshfield Clinic,
Wound Complications and Treatment of the Infected Implantable Cardioverter Defibrillator Generator
Journal of Cardiac Surgery, 1993
Since 1980, the automatic implantable cardioverter defibrillator (ICD) has evolved as effective therapy for prevention of sudden cardiac death following documented sustained ventricular tachycardia or fibrillation. During a 5-year period, 41 2 ICD devices were implanted at the University of Michigan Hospitals with a wound complication rate of 4.1%. In this group, there were 13 infections, 3 erosions of the generator pocket, and 1 wound hematoma. Of the 16 patients with infection or erosion, 12 patients were treated with a rectus abdominis muscle flap closure and 4 with ICD generator removal. In 83% (n = 12) of the muscle flap patients, 672 GUPTA, ET AL.
Management and Outcome of Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infections
Journal of The American College of Cardiology, 2007
We describe the management and outcome of permanent pacemaker (PPM) and implantable cardioverter-defibrillator (ICD) infections in a large cohort of patients seen at a tertiary care facility with expertise in device lead extraction.Infection is a serious complication of PPM and ICD implantation. Optimal care of patients with these cardiac device infections (CDI) is not well defined.A retrospective review of all patients with CDI admitted to Mayo Clinic Rochester between January 1, 1991, and December 31, 2003, was conducted. Demographic and clinical data were collected, and descriptive analysis was performed.A total of 189 patients met the criteria for CDI (138 PPM, 51 ICD). The median age of the patients was 71.2 years. Generator pocket infection (69%) and device-related endocarditis (23%) were the most common clinical presentations. Coagulase-negative staphylococci and Staphylococcus aureus, in 42% and 29% of cases, respectively, were the leading pathogens for CDI. Most patients (98%) underwent complete device removal. Duration of antibiotic therapy after device removal was based on clinical presentation and causative organism (median duration of 18 days for pocket infection vs. 28 days for endocarditis; 28 days for S. aureus infection vs. 14 days for coagulase-negative staphylococci infection [p < 0.001]). Median follow-up after hospital discharge was 175 days. Ninety-six percent of patients were cured with both complete device removal and antibiotic administration.Cure of CDI is achievable in the large majority of patients treated with an aggressive approach of combined antimicrobial treatment and complete device removal. Based on findings of our large retrospective institutional survey and previously published data, we submit proposed management guidelines of CDI.
Pacing and Clinical Electrophysiology, 1998
Be Prevented? Nonthoracotomy ICDs are believed to be the best therapeutic modality for treatment of lifethreatening ventricular arrhythmias. Little is known about the risk of infection with initial implantation of these devices. We studied the incidence, clinical characteristics, and risk factors associated with infections in 1,831 patients with nonthoracotomy ICD from the Endotak-C nonthoracotomy lead registry of Cardiac Pacemakers, Inc. A transvenous lead was implanted in 950 patients (51.9%) and a combination transvenous plus subcutaneous patch was used in 881 patients (48.1%). Nine preselected data variables were studied, and all investigators identified as having patients with infections were personally contacted. Infections occurred in 22 (1.2%) of 1,831 patients receiving this nonthoracotomy ICD system. The mean time to infection was 5.7 ± 6.5 months (range 1-25 months). Staphylococci were isolated in 58% of patients with reported infection. The presence of a subcutaneous defibrillator patch system was associated with the development of infection. Six of 950 patients (0.63%) with a totally transvenous lead system developed infection versus 16 of 838 (1.9%) patients with a transvenous lead plus subcutaneous patch system configuration (P = 0.015,, with an unadjusted estimated odds ratio of 3.06 ). The risk of infection encountered with the nonthoracotomy ICD is low, estimated from our data to be 1.2%. Placement of a subcutaneous defibrillator patch appears to be an independent risk factor for development of infection. (PACE 1998; 21[Pt. I]:42-55) infection, implantable cardioverter defibrillator Implantable cardioverter defibrillators (ICDs) are well-established as a successful therapeutic modality for the treatment of patients with lifethreatening arrhythmias.^^" From the early development of the ICD, Mirowski and Mower appreciated the feasihility and desirability of nonthoracotomy systems.^~^^ However, due to the many formidable technical challenges encoun-Address for reprints: Peter N, Smith, M.D., FACC, Marshfield Clinic,
Clinical Infectious Diseases, 1998
The objective of this report is to describe the characteristics of patients who develop infections associated with implantable cardioverter-defibrillators (ICDs) implanted with sternotomy and thoracotomy approaches. A retrospective chart review identified all patients who underwent ICD implantation at a university medical center from November 1982 through February 1990. Several patient and procedural variables were compared between infected patients and noninfected patients. One hundred fifty-seven patients underwent 202 ICD generator implantations (45 generator changes), and nine of these patients developed infection (4.5% per implantation and 5.7% per patient). Of the patient variables analyzed, a significant correlation (P < .0001) was made only with a diagnosis of diabetes mellitus: 36% of diabetics versus 3.9% of nondiabetics were infected. The only patient- or procedure-specific variable that was found to correlate with the development of infection was the presence of diabetes mellitus.
Delayed infection of the automatic implantable cardioverter-defibrillator
The Journal of Thoracic and Cardiovascular Surgery, 1988
Delayed infection of the automatic implantable cardioverter-defibrillator Current recognition and management Three cases of delayed infection of automatic implantable cardioverter-defibrillator devices without systemic manifestations are reported. Computed tomographic scan of the heart revealed fluid deep to the patch in each case. Sonication of explanted automatic implantable cardioverter-defibrillator patches facilitated the recovery of adherent microorganisms in one case. Management of this previously unrecognized problem is outlined.